Movement Alert|Nutanix Rises 5.26% in Regular Trading, Fiscal Q3 Earnings Significantly Beat Expectations

Market Focus
May 28

On May 28, Nutanix rose 5.26% in regular trading, trading at $48.985/share, with trading volume of $151 million. The rally was driven by the company's fiscal Q3 earnings report, which significantly exceeded market expectations.

Nutanix reported adjusted earnings of $0.47 per diluted share for fiscal Q3 ended April 30, beating the analyst consensus estimate of $0.36 by 30.56% and up from $0.42 in the year-ago period. Revenue came in at $703.1 million, representing 10% year-over-year growth and exceeding the $686.3 million consensus. The company also raised its full-year fiscal 2026 revenue guidance to $2.82–$2.84 billion, compared to the prior analyst consensus of $2.82 billion. Prior to the earnings release, the stock had already pulled back over 6% on expectations of EPS contraction, and the strong beat triggered a rapid rebound as risk-averse capital flowed back in.

However, Morgan Stanley noted that the company's Q4 revenue guidance of $725–$745 million, with a midpoint slightly below the $742.2 million consensus, suggests potential supply chain headwinds and macroeconomic pressures ahead.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10